According to media reports this morning, the US Senate Committee on Aging may soon start contempt proceedings against Canadian drugmaker Valeant Pharmaceuticals International's (TSX: VRX) Michael Pearson. 11 April 2016
Stories about the pharmaceutical industry which have made headline news in recent months have not done the sector’s reputation any favors. 11 April 2016
Representatives of governments, healthcare providers, academia and industry from 15 countries gathered in the UK to explore collaborations aimed at developing their local genomics capability. 8 April 2016
The trade group representing Australia’s biotech industry has moved to clear up confusion over the proposed Australian Innovation and Manufacturing’ (AIM) Incentive. 7 April 2016
The planned $160 billion mega-merger of US pharma giant Pfizer and Ireland-domiciled Allergan will be called off, with an official announcement expected to be released today, according to media reports. 6 April 2016
A critical response has been given to draft new guidance issued by the US Food and Drug Administration on the labeling of biosimilars by the Alliance for Patient Access (AfPA). 5 April 2016
Russia has come one step closer to the establishment of production of foreign drugs at the facilities of domestic enterprises, as the Russian Federal Antimonopoly Service (FAS) has officially announced that it has completed the design of a scheme of compulsory licensing of imported vital drugs. 5 April 2016
The Indonesian government last week released the 11th economic stimulus package with the aim of boosting the domestic production of medicines' raw materials, particularly for five product categories: biotechnology, vaccines, herbal extracts, active pharmaceutical ingredients and medical devices. 4 April 2016
The Australian Minister for Health, Sussan Ley, has announced that patients will see the cost of their prescriptions for common medicines drop by as much as 60% as part of government reforms. 4 April 2016
US Congress has written to the National Institutes of Health (NIH) questioning the price Americans are charged for the prostate cancer drug Xtandi (enzalutamide) by Japanese company Astellas Pharma. 30 March 2016
The outgoing chief executive of under-siege Canadian drugmaker Valeant Pharmaceuticals will be grilled by a US Senate panel over rising drug prices. 29 March 2016
The Russian Parliament (State Duma) will consider a draft of a new federal law that will establish a state monopoly on the production of drugs in Russia, reports The Pharma Letter’s local correspondent. 24 March 2016
In the next five years, where is China’s pharma industry heading to? How should pharma companies allocate their resources to ensure the reward? The answers lie in the recently released guidance for the pharma industry five-year development from China’s top authority – the State Council, reports The Pharma Letter’s local correspondent Wang Fangqing. 22 March 2016
The UK government has committed to renegotiate its membership of the European Union and to giving the UK electorate the chance, in a referendum, to choose between the revised membership terms or “Brexit.” 17 March 2016
Stephen Ubl, president and chief executive of the Pharmaceutical Research and Manufacturers of America (PhRMA), is optimistic that the association’s series of policy proposals can help to prompt a bright new period in drug discovery. 15 March 2016
Global drugmakers operating in Russia may totally refuse to supply imports of cheap drugs to the country, due to unprofitability and economic futility, according to recent statements of Veronika Skvortsova, Russia’s Ministry of Health. 14 March 2016
The Indian government will not take any decision on drug price control without holding discussions with the pharmaceutical industry and other stakeholders, Union Minister of State for Chemicals and Fertilisers, Hansraj Gangaram Ahir, said at an ASSOCHAM (The Associated Chambers of Commerce & Industry of India) event held in New Delhi today. 10 March 2016
The USA’s Office of the Assistant Secretary for Planning and Evaluation (ASPE) this week released its Observations on trends in prescription drug spending, noting that expenditures on Rx medicines are rising and are projected to continue to rise faster than overall health spending thereby increasing this sector’s share of health care spending. 9 March 2016
The US Department of Health and Human Services (HHS) has released final guidance for the second cycle of Medicare drug price negotiations. 3 October 2024
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
The Danish government is to remove the rules that currently prohibit the purchase of medicines from countries outside the European Union (EU) in a move that has not been welcomed by pharma. 30 September 2024
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Global leaders have approved a political declaration at the 79th United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR). 30 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
US biotech Emergent BioSolutions revealed it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio. 26 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
President Biden has said the USA will commit at least $500 million to support African countries in battling the ongoing mpox outbreak in Central and Eastern Africa. 25 September 2024
The Pharmaceutical Research and Manufacturers of America (PhRMA) is continuing its legal challenge against the US government’s drug pricing reforms. 24 September 2024
The Foundation for Economic and Industrial Research and Greek pharma trade group the Hellenic Association of Pharmaceutical Companies have presented two studies reflecting the industry’s importance. 23 September 2024
Basilea Pharmaceutica announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) has awarded Basilea an Other Transaction Agreement (OTA), under OTA number 75A50124C00033. 20 September 2024
Novo Nordisk is under increasing pressure over the cost of its blockbuster drugs in the USA, as chief executive Lars Fruergaard Jørgensen prepares to testify before a powerful Senate committee. 18 September 2024
The research based pharmaceutical industry has welcomed Mario Draghi’s report, published by the European Commission, outlining proposals on how Europe can regain its competitive edge and the critical role of innovative industries in achieving this. 11 September 2024
Even as emerging signs of a thaw in the broader Indian start-up funding landscape were evident, the Competition Commission of India (CCI) has tightened its exemption list under new combination rules. 11 September 2024
The US House of Representatives has passed the BIOSECURE Act, gaining bipartisan support with a vote of 306–81. Nearly all of the votes against the bill came from Democrats. 10 September 2024
The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted what it regards as the UK's potential to lead the global cell and gene therapy sector. 5 September 2024
The budget on October 30 is an opportunity to end short-termism, cut waste, and attract long-term investment to the country’s economy with a sector-targeted R&D tax relief policy, according to the UK BioIndustry Association (BIA). 3 September 2024
The Danish Pharmaceutical Industry Association, Lif, has given its verdict on the government financial bill setting out new priorities in health in 2025. 2 September 2024
Marseille-based ImCheck Therapeutics has received 20.2 million euros ($22.4 million) in non-dilutive funding as part of the i-Démo call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. 29 August 2024